Your session is about to expire
← Back to Search
Spartalizumab Safety for Cancer
Study Summary
This trial is assessing the safety and tolerability of spartalizumab, and will allow subjects already receiving the treatment to continue doing so.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 172 Patients • NCT02325739Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was taken off spartalizumab for reasons other than joining another study.I am currently in a Novartis study and receiving spartalizumab.I am benefiting from the current treatment, as confirmed by my doctor.I am currently in a Novartis study and receiving spartalizumab alone or with other treatments.There may be other requirements to participate in the study as outlined in the study guidelines.
- Group 1: PDR001
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there supplementary investigations involving PDR001?
"The first research into PDR001 was performed at UCLA School of Medicine in 2011 and since then, 21 studies have been wrapped up. At present, there are 27 ongoing clinical trials being conducted with a focus on Portland, Oregon."
Does this investigation represent a pioneering effort in the field?
"Since its first clinical trial in 2011, which was sponsored by Novartis Pharmaceuticals and included 185 participants, PDR001 has been studied extensively. After receiving Phase 1 drug approval the research went global - now there are 27 active trials involving 122 cities across 35 countries."
How many participants are accepted for this medical experiment?
"To successfully complete this trial, 121 suitable candidates must be recruited. Potential participants can apply to the Providence Portland Medical Centre in Oregon or Columbia University Medical Center- New york Presbyterian in NYC."
Does this medical trial have open enrollment or is it closed?
"Clinicaltrials.gov confirms that this medical trial is still searching for participants, with the initial posting on October 31st 2019 and last update occurring on August 29th 2022."
Has the FDA sanctioned PDR001 for medical use?
"This clinical trial is only in its infancy, so there is limited data regarding PDR001's safety and efficacy. Consequently, it was given a score of 1 on our assessment scale."
At how many sites is this trial currently being conducted?
"There are 5 sites offering this clinical trial, amongst them the Providence Portland Medical Center in Portland and Columbia University Medical Centre-New york Presbyterian in New York. Additionally, MD Anderson Cancer Centre/University of Texas MDACC is recruiting patients from Toronto as well as other locations."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger